Moderna Just Eliminated This 1 Risk
Moderna (NASDAQ: MRNA) delivered one piece of bad news to investors a few months ago: Chief medical officer (CMO) Tal Zaks will depart in September. The news came during the initial rollout of Moderna's very first product: its coronavirus vaccine. Zaks has been with the company for six years, and shepherded the vaccine from early-stage development through authorization. So, Moderna was about to lose a key character in its coronavirus vaccine story.
Moderna allayed investor fears this week, however. The company announced its new hire -- but not just any new hire. This individual comes to Moderna right from fellow coronavirus-vaccine maker Johnson & Johnson (NYSE: JNJ). Let's take a closer look at how the news eliminates a risk for the biotech company.
Image source: Getty Images.
Source Fool.com
